• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

    25.01 +1.21 (+5.08%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,593,773
    Open 23.80
    Bid (Size) 24.10 (1)
    Ask (Size) 25.26 (9)
    Prev. Close 23.80
    Today's Range 23.50 - 26.17
    52wk Range 13.53 - 35.25
    Shares Outstanding 79,199,501
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday
     
    Via Benzinga
    Topics Artificial Intelligence
    Jefferies Initiates Beam Therapeutics with "Buy" Rating, Eyeing Promising Gene-Editing Pipeline and Upcoming Catalysts
    New York, NY – October 9, 2025 – In a significant move set to ripple through the biotech sector, Jefferies has initiated coverage of Beam Therapeutics (NASDAQ: BEAM) with a coveted "Buy" rating. This... 
    Via MarketMinute

    Performance

    YTD
    +1.3%
    +1.3%
    1 Month
    +3.6%
    +3.6%
    3 Month
    +32.8%
    +32.8%
    6 Month
    +23.6%
    +23.6%
    1 Year
    +14.1%
    +14.1%

    More News

    Read More
    Jim Cramer Sees More Upside For Shopify, Likes CoreWeave's AI Moves
    Via Benzinga
    Topics Artificial Intelligence
    Is Beam Therapeutics Gaining or Losing Market Support?
    Via Benzinga
    What Does the Market Think About Beam Therapeutics?
    Via Benzinga
    Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors
    Via MarketMinute
    Topics Artificial Intelligence Climate Change Economy
    My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years
    Via Benzinga
    Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
    Via MarketMinute
    Topics Artificial Intelligence Economy Emissions
    Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
    From Beam Therapeutics
    Via GlobeNewswire
    Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease
    Via Benzinga
    Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
    From Beam Therapeutics
    Via GlobeNewswire
    Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)
    From Beam Therapeutics
    Via GlobeNewswire
    10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
    Via The Motley Fool
    Topics Artificial Intelligence
    Cathie Wood's Ark Invest Continues To Offload Coinbase, Bets Big On SoFi Technologies
    Via Benzinga
    The FDA Shake-Up Continues, And Could Impact Genetic Medicines
    Via Investor's Business Daily
    Topics Government
    Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
    Via Benzinga
    Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
    Via Investor's Business Daily
    Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress
    From Beam Therapeutics
    Via GlobeNewswire
    Cathie Wood's Ark Invest Continues To Offload Palantir, Loads Up On Beam Therapeutics, GitLab
    Via Benzinga
    Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
    From Beam Therapeutics
    Via GlobeNewswire
    Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
    From Beam Therapeutics
    Via GlobeNewswire
    BioMedNewsBreaks — Beam Therapeutics Inc. (NASDAQ: BEAM) to Present New Sickle Cell Data from BEACON Trial at EHA2025
    Via Investor Brand Network
    Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress
    From Beam Therapeutics
    Via GlobeNewswire
    Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference
    From Beam Therapeutics
    Via GlobeNewswire
    Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
    From Beam Therapeutics
    Via GlobeNewswire

    Frequently Asked Questions

    Is Beam Therapeutics Inc. - Common Stock publicly traded?
    Yes, Beam Therapeutics Inc. - Common Stock is publicly traded.
    What exchange does Beam Therapeutics Inc. - Common Stock trade on?
    Beam Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Beam Therapeutics Inc. - Common Stock?
    The ticker symbol for Beam Therapeutics Inc. - Common Stock is BEAM on the Nasdaq Stock Market
    What is the current price of Beam Therapeutics Inc. - Common Stock?
    The current price of Beam Therapeutics Inc. - Common Stock is 25.01
    When was Beam Therapeutics Inc. - Common Stock last traded?
    The last trade of Beam Therapeutics Inc. - Common Stock was at 10/31/25 04:00 PM ET
    What is the market capitalization of Beam Therapeutics Inc. - Common Stock?
    The market capitalization of Beam Therapeutics Inc. - Common Stock is 1.98B
    How many shares of Beam Therapeutics Inc. - Common Stock are outstanding?
    Beam Therapeutics Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.